## Mark G Lewis

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/1366055/mark-g-lewis-publications-by-year.pdf

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

88	8,140 citations	31	90
papers		h-index	g-index
98	11,434 ext. citations	28.3	5.46
ext. papers		avg, IF	L-index

#	Paper	IF	Citations
88	Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters <i>Npj Vaccines</i> , <b>2022</b> , 7, 2	9.5	O
87	Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates <i>Npj Vaccines</i> , <b>2022</b> , 7, 7	9.5	7
86	A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques <i>Med</i> , <b>2022</b> ,	31.7	1
85	Vaccine Protection Against the SARS-CoV-2 Omicron Variant in Macaques. <b>2022</b> ,		2
84	A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates. <i>Science Translational Medicine</i> , <b>2022</b> , 14,	17.5	9
83	SARS-CoV-2 receptor binding domain displayed on HBsAg virus-like particles elicits protective immunity in macaques <i>Science Advances</i> , <b>2022</b> , 8, eabl6015	14.3	3
82	Vaccine protection against the SARS-CoV-2 Omicron variant in macaques Cell, 2022,	56.2	3
81	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron <i>Cell</i> , <b>2022</b> ,	56.2	22
80	A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2-specific immune responses in rhesus macaques <i>Science Translational Medicine</i> , <b>2022</b> , eabm	14996	1
79	Reduced Pathogenicity of the SARS-CoV-2 Omicron Variant in Hamsters Med, 2022,	31.7	13
78	Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates <i>PLoS Biology</i> , <b>2022</b> , 20, e3001609	9.7	О
77	Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques <i>Npj Vaccines</i> , <b>2022</b> , 7, 53	9.5	О
76	Optimization of Non-Coding Regions for a Non-Modified mRNA COVID-19 Vaccine. <i>Nature</i> , <b>2021</b> ,	50.4	9
75	Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung <i>Cell</i> , <b>2021</b> ,	56.2	24
74	Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates. <i>Science</i> , <b>2021</b> , 374, 1343-1353	33.3	32
73	Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airway <b>2021</b> ,		4
72	Protective Efficacy of Gastrointestinal SARS-CoV-2 Delivery Against Intranasal and Intratracheal SARS-CoV-2 Challenge in Rhesus Macaques. <i>Journal of Virology</i> , <b>2021</b> , JVI0159921	6.6	2

## (2021-2021)

71	A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge. <i>Npj Vaccines</i> , <b>2021</b> , 6, 129	9.5	8
70	Correlates of protection against SARS-CoV-2 in rhesus macaques. <i>Nature</i> , <b>2021</b> , 590, 630-634	50.4	498
69	Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates <b>2021</b> ,		13
68	Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman Primates <b>2021</b> ,		12
67	Engineered SARS-CoV-2 receptor binding domain improves immunogenicity in mice and elicits protective immunity in hamsters <b>2021</b> ,		10
66	Persistence of viral RNA in lymph nodes in ART-suppressed SIV/SHIV-infected Rhesus Macaques. <i>Nature Communications</i> , <b>2021</b> , 12, 1474	17.4	7
65	Immune Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection in Nonhuman Primates <b>2021</b> ,		24
64	Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates. <i>Npj Vaccines</i> , <b>2021</b> , 6, 50	9.5	19
63	Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques <b>2021</b> ,		5
62	Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques. <i>JCI Insight</i> , <b>2021</b> , 6,	9.9	13
61	Evaluation of mRNA-1273 against SARS-CoV-2 B.1.351 Infection in Nonhuman Primates <b>2021</b> ,		2
60	Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. <i>Nature</i> , <b>2021</b> , 594, 553-55	<b>55</b> 0.4	85
59	New SHIVs and Improved Design Strategy for Modeling HIV-1 Transmission, Immunopathogenesis, Prevention and Cure. <i>Journal of Virology</i> , <b>2021</b> ,	6.6	7
58	Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques. <i>Nature</i> , <b>2021</b> , 596, 423-42	2750.4	22
57	A cautionary perspective regarding the isolation and serial propagation of SARS-CoV-2 in Vero cells. <i>Npj Vaccines</i> , <b>2021</b> , 6, 83	9.5	9
56	Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques. <i>Cell</i> , <b>2021</b> , 184, 3467-3473.e11	56.2	23
55	A SARS-CoV-2 spike ferritin nanoparticle vaccine protects against heterologous challenge with B.1.1.7 and B.1.351 virus variants in Syrian golden hamsters <b>2021</b> ,		4
54	A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primates <b>2021</b> ,		3

53	SARS-CoV2 infects pancreatic beta cells in vivo and induces cellular and subcellular disruptions that reflect beta cell dysfunction <b>2021</b> ,		1
52	Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. <i>Science</i> , <b>2021</b> , 371,	33.3	22
51	SARS-CoV-2 vaccination induces neutralizing antibodies against pandemic and pre-emergent SARS-related coronaviruses in monkeys <b>2021</b> ,		4
50	Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. <i>Science Translational Medicine</i> , <b>2021</b> , 13,	17.5	17
49	SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution. <i>Nature Microbiology</i> , <b>2021</b> , 6, 1188-1198	26.6	105
48	In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. <i>Cell</i> , <b>2021</b> , 184, 4203-4219.e32	56.2	89
47	Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Boosted Nonhuman Primates <b>2021</b> ,		8
46	mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. <i>Nature Immunology</i> , <b>2021</b> , 22, 1306-1315	19.1	32
45	Immunity elicited by natural infection or Ad26.COV2.S vaccination protects hamsters against SARS-CoV-2 variants of concern. <i>Science Translational Medicine</i> , <b>2021</b> , 13, eabj3789	17.5	13
44	Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants. <i>Science Translational Medicine</i> , <b>2021</b> , 13, eabj2641	17.5	8
43	Synthetic Multiantigen MVA Vaccine COH04S1 Protects Against SARS-CoV-2 in Syrian Hamsters and Non-Human Primates <b>2021</b> ,		2
42	Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. <i>Science</i> , <b>2021</b> , 373, eabj0299	33.3	86
41	Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2021</b> , 118,	11.5	12
40	Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaques. <i>PLoS Pathogens</i> , <b>2021</b> , 17, e1009701	7.6	4
39	Intradermal-delivered DNA vaccine induces durable immunity mediating a reduction in viral load in a rhesus macaque SARS-CoV-2 challenge model. <i>Cell Reports Medicine</i> , <b>2021</b> , 2, 100420	18	9
38	Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2021</b> , 118,	11.5	13
37	Low-Dose Ad26.COV2.S Protection Against SARS-CoV-2 Challenge in Rhesus Macaques <b>2021</b> ,		8
36	Development of an Probe to Track SARS-CoV-2 Infection in Rhesus Macaques <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 810047	8.4	1

## (2017-2021)

35	Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2 <i>Npj Vaccines</i> , <b>2021</b> , 6, 156	9.5	2
34	SARS-CoV-2 infection protects against rechallenge in rhesus macaques. <i>Science</i> , <b>2020</b> , 369, 812-817	33.3	592
33	DNA vaccine protection against SARS-CoV-2 in rhesus macaques. <i>Science</i> , <b>2020</b> , 369, 806-811	33.3	748
32	Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates <b>2020</b> ,		20
31	Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques. <i>Cell</i> , <b>2020</b> , 183, 185-196.e14	56.2	11
30	REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. <i>Science</i> , <b>2020</b> , 370, 1110-1115	33.3	330
29	Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. <i>Nature</i> , <b>2020</b> , 586, 583-588	50.4	550
28	Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus Macaques. <i>Cell</i> , <b>2020</b> , 183, 1354-1366	. <b>65</b> 1632	108
27	Animal models for COVID-19. <i>Nature</i> , <b>2020</b> , 586, 509-515	50.4	377
26	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 1544-1555	59.2	612
25	Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters. <i>Nature Medicine</i> , <b>2020</b> , 26, 1694-1700	50.5	176
24	Lack of therapeutic efficacy of an antibody to IIn SIVmac251-infected rhesus macaques. <i>Science</i> , <b>2019</b> , 365, 1029-1033	33.3	21
23	Targeted selection of HIV-specific antibody mutations by engineering B cell maturation. <i>Science</i> , <b>2019</b> , 366,	33.3	60
22	TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy. <i>Science Translational Medicine</i> , <b>2018</b> , 10,	17.5	87
21	Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. <i>Journal of Experimental Medicine</i> , <b>2018</b> , 215, 1571-1588	16.6	212
20	Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. <i>Nature</i> , <b>2018</b> , 563, 360-364	50.4	155
19	Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. <i>Nature</i> , <b>2017</b> , 543, 248-251	50.4	502
18	Zika Virus Persistence in the Central Nervous System and Lymph Nodes of Rhesus Monkeys. <i>Cell</i> , <b>2017</b> , 169, 610-620.e14	56.2	139

17	Durability and correlates of vaccine protection against Zika virus in rhesus monkeys. <i>Science Translational Medicine</i> , <b>2017</b> , 9,	17.5	80
16	Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys. <i>Nature</i> , <b>2016</b> , 540, 284-287	50.4	183
15	Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, E3413-22	11.5	132
14	Zika viral dynamics and shedding in rhesus and cynomolgus macaques. <i>Nature Medicine</i> , <b>2016</b> , 22, 1448-	-1 <del>5</del> 45.5	228
13	Rapid development of a DNA vaccine for Zika virus. <i>Science</i> , <b>2016</b> , 354, 237-240	33.3	284
12	Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. <i>Science</i> , <b>2016</b> , 353, 1129-32	33.3	386
11	Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. <i>Science</i> , <b>2015</b> , 349, 320-4	33.3	236
10	Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. <i>Nature</i> , <b>2014</b> , 512, 74-7	50.4	403
9	Type I interferon upregulates Bak and contributes to T cell loss during human immunodeficiency virus (HIV) infection. <i>PLoS Pathogens</i> , <b>2013</b> , 9, e1003658	7.6	68
8	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron		12
7	An intranasally administrated SARS-CoV-2 beta variant subunit booster vaccine prevents beta variant viral replication in rhesus macaques		1
6	Reduced Pathogenicity of the SARS-CoV-2 Omicron Variant in Hamsters		19
5	Recapitulation of HIV-1 Env-Antibody Coevolution in Macaques Leading to Neutralization Breadth		1
4	Intradermal-delivered DNA vaccine provides anamnestic protection in a rhesus macaque SARS-CoV-2 challenge model		38
3	REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamst	:ers	15
2	New SHIVs and Improved Design Strategy for Modeling HIV-1 Transmission, Immunopathogenesis, Prevention and Cure		1
1	Optimization of Non-Coding Regions Improves Protective Efficacy of an mRNA SARS-CoV-2 Vaccine in Nonhuman Primates		4